Search

Savara Inc

Fechado

SetorSaúde

4.63 -1.49

Visão Geral

Variação de preço das ações

24h

Atual

Mín

4.66

Máximo

4.98

Indicadores-chave

By Trading Economics

Rendimento

-2.8M

-43M

EPS

-0.17

Funcionários

70

EBITDA

-3.4M

-43M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+154.24% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

63M

1B

Abertura anterior

6.12

Fecho anterior

4.63

Savara Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

12 de nov. de 2026, 22:01 UTC

News

Savara Inc. grants inducement awards to seven new employees, including options for 20.5k shares at an exercise price of $4.92 per share.

11 de nov. de 2026, 21:02 UTC

News

Savara Inc. is advancing in price ahead of its PDUFA date on November 22, with unusually high trading volume attracting investor interest.

10 de nov. de 2026, 21:07 UTC

Savara Inc. shares fell sharply, reversing earlier gains to close significantly below their opening level, reaching their lowest point in the afternoon.

9 de nov. de 2026, 23:41 UTC

Savara Inc. is trading higher in after-market hours, reaching its highest cumulative return since Monday's close and maintaining strong upward momentum.

6 de nov. de 2026, 21:02 UTC

Savara Inc. shares are advancing, showing a significant increase since Thursday's close, with unusually high trading volume despite earlier pulling back from a session high.

5 de nov. de 2026, 21:04 UTC

Correlated Moves

Savara Inc. shares fell sharply, reflecting a broader decline in the biotechnology sector, as the SPDR S&P Biotech ETF also experienced significant losses.

4 de nov. de 2026, 20:52 UTC

Savara Inc. shares fell sharply, remaining below their 20-day moving average amid unusually high market volume and significant fluctuations earlier in the session.

3 de nov. de 2026, 21:07 UTC

Savara Inc. shares are advancing, building on Monday's close, despite pulling back from an earlier session high amid overall modest market gains.

2 de nov. de 2026, 23:06 UTC

Savara Inc. shares advanced in after-market trading, gaining ground since Monday's close, following three consecutive sessions that finished lower.

30 de out. de 2026, 20:08 UTC

Savara Inc. shares fell significantly, reflecting broader market weakness, and finished notably lower compared to Thursday's close.

29 de out. de 2026, 20:06 UTC

Savara Inc. shares fell sharply as the broader market closed lower after an early peak.

28 de out. de 2026, 20:02 UTC

Savara Inc. shares are advancing, diverging from a broader market downturn observed during Wednesday's session.

27 de out. de 2026, 21:01 UTC

Savara Inc. shares declined modestly in after-market trading, remaining near the bottom of their range after a notable drop earlier in the session.

26 de out. de 2026, 23:56 UTC

Savara Inc's shares advanced in after-market trading, reflecting a notable rise since Monday's close, though still below its 20-day moving average.

23 de out. de 2026, 21:02 UTC

Savara Inc shares advanced in after-market trading, reaching a high shortly after the market closed before settling to a more modest gain.

22 de out. de 2026, 20:07 UTC

News

Savara Inc's stock is declining after the company reiterated its Market Outperform rating and $10 price target, following new Molbreevi data presented at the CHEST conference.

21 de out. de 2026, 23:16 UTC

Savara Inc is trading higher in after-market hours, gaining since Wednesday's close.

20 de out. de 2026, 23:06 UTC

Savara Inc. shares advanced modestly in after-market hours, following a session that saw earlier peak gains before settling lower.

19 de out. de 2026, 22:51 UTC

Savara Inc shares are moving higher in after-market trading, supported by an upward trend in the broader market, despite earlier session pullbacks.

16 de out. de 2026, 22:26 UTC

Savara Inc shares traded lower in after-market hours, reflecting ongoing weakness amid broader market concerns over rising U.S. import and export prices.

15 de out. de 2026, 23:06 UTC

Savara Inc's shares are advancing in after-market trading, gaining ground since Thursday's close, with a cumulative return peaking at just under 1.9%.

14 de out. de 2026, 19:36 UTC

Savara Inc shares fell modestly on Wednesday, retracing from an early peak and remaining under pressure below their 20-day moving average.

13 de out. de 2026, 20:13 UTC

Savara Inc shares advanced in after-market trading, continuing their upward trend since Tuesday's close, though still below the 20-day moving average.

12 de out. de 2026, 19:36 UTC

Social Media

Savara Inc shares are declining, having pulled back from an earlier high in pre-market hours, and are currently below their 20-day moving average.

9 de out. de 2026, 19:55 UTC

Social Media

JPMorgan sets a price target of $12 for Savara Inc, noting catalysts including anticipated UK approval in Q4 and a MAA in Q1 for molgramostim.

8 de out. de 2026, 23:25 UTC

Savara Inc shares advanced during after-market hours on Thursday, settling at a solid gain.

7 de out. de 2026, 20:01 UTC

News
Social Media

Savara Inc shares are trading sharply higher as JP Morgan initiated coverage with an Overweight rating and a $12 price target ahead of its PDUFA date.

6 de out. de 2026, 20:00 UTC

Savara Inc shares fell, breaking a trend of higher daily closes, indicating a shift in momentum following Monday's close.

2 de out. de 2026, 20:01 UTC

Savara Inc shares fell sharply, experiencing significant volatility and trading below their 20-day moving average amid high market volume.

1 de out. de 2026, 19:46 UTC

Social Media

Savara Inc shares are trading lower as heightened short interest and increased volume coincide with the approach of its PDUFA date for molgramostim.

Comparação entre Pares

Variação de preço

Savara Inc Previsão

Preço-alvo

By TipRanks

154.24% parte superior

Previsão para 12 meses

Média 12 USD  154.24%

Máximo 16 USD

Mínimo 10 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Savara Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

5

Comprar

0

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
help-icon Live chat